GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Debt-to-EBITDA

Onconetix (Onconetix) Debt-to-EBITDA : -0.36 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Onconetix Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Onconetix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.24 Mil. Onconetix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.16 Mil. Onconetix's annualized EBITDA for the quarter that ended in Mar. 2024 was $-42.48 Mil. Onconetix's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Onconetix's Debt-to-EBITDA or its related term are showing as below:

ONCO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.35   Med: -0.27   Max: -0.27
Current: -0.35

During the past 5 years, the highest Debt-to-EBITDA Ratio of Onconetix was -0.27. The lowest was -0.35. And the median was -0.27.

ONCO's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs ONCO: -0.35

Onconetix Debt-to-EBITDA Historical Data

The historical data trend for Onconetix's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix Debt-to-EBITDA Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- - - - -0.27

Onconetix Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.50 -0.64 -0.11 -0.36

Competitive Comparison of Onconetix's Debt-to-EBITDA

For the Biotechnology subindustry, Onconetix's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onconetix's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Onconetix's Debt-to-EBITDA falls into.



Onconetix Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Onconetix's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.693 + 0.193) / -36.707
=-0.27

Onconetix's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.244 + 0.158) / -42.48
=-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Onconetix  (NAS:ONCO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Onconetix Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Onconetix's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Onconetix (Onconetix) Business Description

Traded in Other Exchanges
Address
201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Executives
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic director BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc 10 percent owner 2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc other: Manager-Cinti Cornerstone Inv. 2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez 10 percent owner, officer: CEO C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson officer: Chief Business Officer 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield officer: CFO 11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable director 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202

Onconetix (Onconetix) Headlines

From GuruFocus